Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxyne Limited ( (AU:BXN) ) has shared an announcement.
Bioxyne Limited has applied for quotation on the ASX of 1,267,797 ordinary fully paid shares, to be issued on 14 April 2026 under its BXN ticker. The new securities arise from the exercise or conversion of existing options or other convertible instruments, incrementally increasing the company’s listed share base and providing additional tradable equity for investors.
The move formalises the transition of these previously unquoted or convertible interests into fully quoted ordinary shares, enhancing liquidity in Bioxyne’s stock. While the filing is procedural, it reflects ongoing utilisation of equity-based instruments in the company’s capital management and could modestly broaden its shareholder register and free float over time.
More about Bioxyne Limited
Bioxyne Limited, listed on the ASX under the code BXN, is an Australian company whose latest filing relates to the quotation of its ordinary fully paid shares. The business operates within the listed equities market framework of the Australian Securities Exchange, with its capital structure disclosed through standard ASX corporate actions and appendices.
Average Trading Volume: 3,767,624
Technical Sentiment Signal: Buy
Current Market Cap: A$149.8M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.